Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced that CEO Thomas K. Equels will present at the Inaugural Emerging Growth Virtual Conference, held from March 17-19, 2021. The conference features discussions with C-suite executives and presentations from numerous issuers in the healthcare sector. Attendees can access exclusive content by signing up as M-Vest members. AIM will also make its presentation available on its investor relations website. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech has commenced its Phase 1 clinical trial to evaluate the safety of Ampligen as an intranasal therapy for COVID-19 and other respiratory viral diseases. Conducted by the Centre for Human Drug Research in the Netherlands, the study will involve 40 healthy subjects. Positive preliminary in vitro results indicate that Ampligen can decrease SARS-CoV-2 viral yields by 90%. CEO Thomas K. Equels expressed optimism about Ampligen's potential in preventing COVID-19 transmission.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation will be available on-demand starting March 9 at 7:00 AM Eastern Time. Registered attendees can access the webcast through the conference platform or the investor relations section of AIM's website. Additionally, management will engage in one-on-one meetings with qualified investors attending the event.
AIM ImmunoTech has received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen, aimed at treating pancreatic cancer. This designation grants AIM up to ten years of market exclusivity in the EU. Ampligen is expected to be a significant treatment option, with potential survival benefits demonstrated in trials. The company is currently pursuing further studies and FDA fast-track status to expedite its clinical development.
AIM ImmunoTech Inc. (NYSE American: AIM) has received Ethics Committee approval in the Netherlands for its Phase 1 clinical study of Ampligen as an intranasal therapy for COVID-19 and respiratory viral diseases. The study will enroll 40 healthy subjects to evaluate safety and tolerability over 13 days. CEO Thomas K. Equels expressed optimism about the potential of Ampligen, noting previous results that showed a 90% reduction in SARS-CoV-2 infection in vitro. Enrollment is expected to start in Q1 2021.
AIM ImmunoTech has received approval from the Dutch Health and Youth Care Inspectorate for a new Early Access Program to treat pancreatic cancer patients with rintatolimod (Ampligen) at Erasmus Medical Center. The initiative follows the success of a prior program, which demonstrated a significant survival benefit. Up to 16 patients will be treated, and the program aims to enhance patient selection. AIM plans to advance to clinical trials in the EU and U.S., seeking Fast Track status to expedite approval. The orphan drug designation offers ten years of market protection.
AIM ImmunoTech Inc. (AIM) has completed its At-The-Market (ATM) facility and closed its Equity Distribution Agreement (EDA). The company asserts it has sufficient funds to support its operational needs and clinical trials for the next 24 months. AIM plans to independently finance key developmental programs in oncology, COVID-19, ME/CFS, and Long COVID, aiming for significant advancements in 2021. CEO Thomas K. Equels highlighted the company's financial stability and commitment to achieving objectives without a renewed ATM facility.
AIM ImmunoTech has partnered with the Centre for Human Drug Research to conduct a clinical study on its Ampligen drug as an intranasal therapy for COVID-19. The study, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen," will enroll 40 healthy subjects and is fully funded by AIM. Results may provide crucial insights into the potential of Ampligen as a COVID-19 treatment, though future success is uncertain and dependent on many factors.
AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
